The academic-entrepreneur model built companies and minted millionaires. What happens when one of its earliest advocates quits?

Ryan Cross

Senior Science Correspondent

CAMBRIDGE, Mass. — For years in a small handful of US research and venture capital hot spots, a careful balance has brought prestige and wealth to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The academic-entrepreneur model built companies and minted millionaires. What happens when one of its earliest advocates quits?

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

The aca­d­e­m­ic-en­tre­pre­neur mod­el built com­pa­nies and mint­ed mil­lion­aires. What hap­pens when one of its ear­li­est ad­vo­cates quits?

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

The academic-entrepreneur model built companies and minted millionaires. What happens when one of its earliest advocates quits?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals